The International Journal of Indian Psychology
ISSN 2348-5396 (Online) | ISSN: 2349-3429 (Print)
Volume 13, Issue 4, October- December, 2025
DIP: 18.01.150.20251304, DOI: 10.25215/1304.150
https://www.ijip.in

Research Paper

Epigenetic Pathways Linking Environmental Exposures to Autism Spectrum Disorder Risk

Sadhana Sivanandam[1]*

ABSTRACT

Autism Spectrum Disorder (ASD) is a neurodevelopmental disorder that is complex and involves repetitive behaviours and impairments in social communication. Despite the involvement of many genetic loci, genetic factors are not sufficient to explain the clinical diversity of ASD. There is growing evidence that epigenetic mechanisms, such as DNA methylation, histone modification and non-coding RNAs, are dynamically involved as genes and environmental exposures interact**.** The paper is a synthesis of multidisciplinary literature on genetics, neurobiology, and environmental health to assess how prenatal and early-life exposures to certain factors disrupt epigenetic regulation (maternal nutrition, metabolic disorders, stress, parental age, and exposure to toxicants e.g., heavy metals, pesticides, endocrine disruptors) and cause ASD. The systematic review and synthesis conceptually assessed studies on gene-environment (GxE) interactions, transgenerational inheritance and biomarkers. It has been shown that the exposure to the environment alters the process of methylation and chromatin of neurodevelopmental genes (MECP2, OXTR, RELN), which affects brain connectivity and behavior. The GxE interactions increase the risk in genetically vulnerable individuals, and a few of these epigenetic changes are transgenerational. Placenta, cord blood and saliva epigenetic biomarkers have potential of early diagnosis. Notably, the epigenetic changes can be reversed, and this presents a possibility of nutritional, pharmacological, and behavioral intervention. ASD occurs as a result of interaction between genomic vulnerability to a particular condition and environmental influences that interact with epigenetic control. The understanding of epigenetics redefines ASD as a modifiable process and approves new strategies of prevention, precision medicine, and early intervention. The future research is needed to determine causality, enhance the validity of biomarkers and deal with ethical issues in predictive epigenetics.

Keywords: *Autism Spectrum disorder, Epigenetic Regulation, Epigenetic Biomarkers, DNA Methylation, Transgenerational Inheritance*

Autism spectrum disorders (ASD) are a diverse set of neurodevelopmental disorders characterized by fundamental impairments in social interaction and communication, restrictive interests, and repetitive behaviors that manifest themselves before the age

[1]Sri Chaitanya Sr. Secondary School, Tamil Nadu, India
*Corresponding Author

Received: November 10, 2025; Revision Received: November 27, 2025; Accepted: December 01, 2025

of 3 (American Psychiatric Association, 2013). The prevalence estimates that around 1 in 36 children in the United States is diagnosed with ASD, which is attributable to the increasing awareness levels as well as to the input of multifactorial etiologies (Maenner et al., 2023).

Heterogeneity and Multifactorial Etiology of ASD

The etiology underlying ASD is highly complicated, as many of the diagnostic symptoms have a large degree of variability in their severity.The mechanism implicated in ASD is a highly complex combination of genetic, epigenetic, immune and environmental factors that may occur in varying proportions, at varying stages of development (prenatal, perinatal or postnatal) and on varied pathways (Rusu et al., 2015). A female with ASD has higher impairments in terms of social communications and lower cognitive ability, reduced levels of narrowed interests, weak adaptive skills, and also, more difficulty externalizing problems as compared to a male. Interestingly, second-born male siblings are at a higher risk of ASD than second-born female siblings (Guidotti, A., and Grayson, D. R., (2015). Over the past few years, epigenetics has become a promising explanatory model that can explain how environmental factors impact neurodevelopment. Epigenetic processes (e.g., DNA methylation, histone modification, non-coding RNA regulation) are molecular intermediates of changing gene expression without altering the DNA base sequence (Bird, 2007).

Rising Prevalence and Public Health Significance

ASD prevalence in the USA has been growing over time; in 2012, it was 1 in 88 (boys 1 in 54 and girls 1 in 252), as compared to 2012 (CDC, 2012). This more recent surge has identified environmental factors as a central concern to ASD determinism and spurred research in this field.Surprisingly, the study demonstrated that ASD may be provoked not only by classical external environmental factors (e.g. toxicants, pollutants, pesticides), but by maternal imbalances or disorders (e.g. hormonal or inflammatory) and by the disruption of gut microbiota of the affected child (treated as internal environment). Endocrine disruptors like bisphenol A (BPA) and phthalates are also reported to change the DNA methylation patterns of genes associated with neurodevelopmental changes, potentially contributing to the pathogenesis of ASD (Kundakovic and Champagne, 2015). It has been reported that genetic approaches have implicated more than 100 syndromic associated genes and more than 400 high-confidence, nonsyndromic related autism genes. It is interesting to note that not every child with a pre-disposing genotype develops ASD. This implies that other environmental factors are most likely to interact with the genome to cause ASD. Although it appears obvious that recent findings have been able to advance our comprehension of the genetic factors of ASD, further research is now necessary to further our knowledge of the underlying biology of how different risk genes interact and how the environment influences such interactions (Grayson, D. R., & Guidotti, A. (2015).

Although genetics are significant, single genetic anomalies only contribute a minor proportion of ASD, and genetic mutations can play the role of modifying factors to genetic predisposition of ASD.A critical gap in knowledge exists on whether the effects of environmental chemicals on DNA methylation are specific to genes that cause ASD. The causal relationship between DNA methylation alterations triggered by developmental exposures and the development of adverse neurodevelopmental outcomes is inconclusive through the modulated expression of ASD-vulnerability genes.

Considering the heterogeneity of ASD, it is a significant field to be studied in the future with clinical implications to clarify the role of these factors in the determination of the extent of impairment (Keil and Lein, 2016).

Although it is agreeable that more research is needed in the epigenetics area with regards to ASD, improved comprehension of these epigenetic processes may be important in preventing ASD and prevention strategies by targeting modifiable maternal factors and their epigenetic effects.Further research is necessary to fully understand the prospect of multigenerational epigenetics in precision medicine. This entails the successful integration of genetic, environmental and lifestyle elements to suit the variable etiology and clinical manifestations of ASD.

This review seeks to discuss the existing evidence on environmental factors that affect the risk of autism spectrum disorder (ASD) via epigenetic interactions, and specifically the interaction between genetic vulnerability, environmental exposures, and epigenetic regulation. Moreover, the review aims at pointing out the new areas of future research that can result in ASD prevention and early diagnosis.

Autism Spectrum Disorder (ASD) is a complicated neurodevelopmental disorder, which is marked by the impairment of social communication, limited interests, and interests in repetitive behaviors (American Psychiatric Association, 2013). Despite the genetic research breakthroughs that have identified hundreds of susceptibility loci and rare de novo mutations that are linked to ASD, genetic factors cannot be identified as a sufficient reason to explain the increasing prevalence of ASD, as well as its wide phenotypic heterogeneity (Sandin et al., 2017). This has brought increased curiosity of the importance of environmental exposures and how they interact with genetic predispositions.

A convincing mechanistic concept that can help to explain the role of environmental factors in ASD risk is epigenetics - heritable yet reversible changes in which genes are regulated without modifying the DNA sequence (LaSalle et al., 2013). The major epigenetic pathways by which the neurodevelopment can be influenced by the environmental insults include DNA methylation, histone modifications, and non-coding RNAs (Schaevitz and Berger-Sweeney, 2012; Kubota and Mochizuki, 2016). It is worth noting that such epigenetic changes usually happen in the context of sensitive developmental periods, and they might be transmitted across generations, highlighting the significance of direct and transgenerational effects (Tordjman et al., 2014; Finegersh and Rompala, 2015).

The current evidence on the role of environmental factors as contributors to ASD risk via epigenetic processes is critically analyzed in this literature review. It combines knowledge based on animal models, epidemiologic research results, molecular research, and translational research. Discussion is based on major areas, namely:

1. Epigenetic mechanisms in ASD,
2. Maternal and prenatal environmental factors,
3. Toxicants and endocrine disruptors,
4. Gene x environment interaction,
5. Transgenerational inheritance
6. Biomarkers and precision medicine, and
7. Future research directions and ethical considerations.

Altogether, the evidence highlights the complexity of interactions between genetics, epigenetics, and environment in the development of ASD risk, and such complexity has important consequences in the prevention, diagnosis, and individualized treatment.

Epigenetic mechanisms in ASD

Epigenetics fills the interaction gap between the environment and genomic control. DNA methylation is also known to silence or activate genes that are important during neurodevelopment, and it usually takes place at CpG dinucleotides (Tremblay & Jiang, 2019). Abnormal methylation is reported in the brains of individuals with ASD, especially those genes linked to synaptic plasticity, neurotransmission and neurogenesis (Loke et al., 2015). As an example, hypermethylation of the oxytocin receptor gene (OXTR) is associated with low expression and poor social behavior of ASD persons (Gregory et al., 2009). Likewise, there is a RELN gene which is a critical gene in the cortical lamination and its methylation and gene expression are altered in ASD cerebellar tissues (Fatemi et al., 2005).

The modification of chromatin is controlled by the histones, including acetylation and methylation, which control the accessibility of chromatin and the processes of transcription. Such environmental influences such as valproic acid, which is an anticonvulsant have been identified to raise the risk of ASD, they do so by suppressing histone deacetylases, and thus changing neural gene expression throughout development (Thakur and Chauhan, 2024). Non-coding RNAs, especially microRNAs, also contribute to post-transcriptional regulation of ASD-related genes, and their dysregulation has been reported in both animal models and in human postmortem brains (Ziats & Rennert, 2014).

By definition, these processes indicate the way environmental influences can forsake "epigenetic signatures" that continue developmentally. Notably, epigenetic changes are reversible, which is why they should be considered distinctly as genetic mutations and have therapeutic potential (Kubota & Mochizuki, 2016).

Maternal and Prenatal Environmental Influences

The in utero environment is a crucial phase where the maternal factor influences the fetal epigenome. Epigenetic impacts are severe in nutritional status, age, obesity and metabolic conditions.

Maternal nutrition: Folate is an important one-carbon metabolite donor that controls the DNA methylation. Periconceptual folic acid has some relation with ASD risk as it may be stabilizing methylation patterns in neurodevelopmental genes (Vellingiri et al., 2022; Schmidt et al., 2011). On the other hand, the deficiency of folate interferes with DNA methylation, and it puts an individual at risk of ASD (Deth et al., 2008). Altered neurodevelopment and increased prevalence of ASD have been associated with vitamin D deficiency, which is also typical of pregnancy (Masini et al., 2020). There is also a lack of trace elements that include zinc and magnesium, which influence neurodevelopmental pathways (Guo et al., 2018).

Maternal age and metabolic status: High parental age was found to be a stable risk factor of ASD. Older fathers cause DNA mutation and epigenetic drift, which results in aberrant methylation signatures related to ASD among children (Masini et al., 2020). Systemic inflammation and maladaptive metabolic programming of the fetal brain increase the risk of ASD, too; it is predisposed by maternal obesity and gestational diabetes (Xu et al., 2014). Such maternal conditions affect the placental DNA methylation in placental tissues and cord blood, which are the possible biomarkers (Bakulski, 2019).

Maternal stress and hormonal factors: Deuteration of cortisol regulation and DNA methylation of physiological stressful genes like NR3C1 during pregnancy may lead to

impairments in fetus development of the brain (Beversdorf et al., 2018). Hormonal imbalances also play a role, as maternal thyroid hormone levels were found to mediate the process of methylation of neuronal migration genes (Roman et al., 2013).

Medication exposure: The histone acetylation is disrupted by prenatal exposure to antiepileptic medications like valproic acid, which induces autism-like phenotype in rodents (Choi et al., 2016). Equally, selective serotonin reuptake inhibitors (SSRIs) have an effect on DNA methylation in serotonin pathways, though epidemiological evidence is inconsistent (Man et al., 2015).

To conclude, epigenetic regulation in pregnancy is intertwined with maternal nutritional status, metabolic health, and environmental exposure, and has downstream implications on neurodevelopment and the risk of ASD.

Toxicants, Endocrine Disruptors, and Oxidative Stress

The environmental toxicants are one of the most widely researched risk factors of ASD, which are not genetic in nature. Air pollution, heavy metals, pesticides, and endocrine-disrupting chemicals (EDCs) all disrupt the developing brain through epigenetic mechanisms.

Air pollution and heavy metals: There has been increased risk of ASD associated with prenatal exposure to air pollution caused by traffic (nitrogen oxides and particulate matter) (Volk et al., 2013). Neurodevelopmental susceptibility is exacerbated by air pollutants that change the DNA methylation in genes implicated with oxidative stress and inflammation (Rusu et al., 2015). The disruption of methylation enzymes, decrease in availability of glutathione, and increase in oxidative stress observed in the ASD pathology are caused by the heavy metals which include mercury, lead, and cadmium (Kinney et al., 2010).

Pesticides: Organophosphates and organochlorines are effective developmental neurotoxicants. Animal studies reveal that prenatal pesticide exposure impairs neuronal connectivity and brings changes in the process of DNA methylation in synaptic genes (Stamou et al., 2013). Pesticides are also associated with ASD outbreaks in agricultural communities as suggested by epidemiological data (Shelton et al., 2014).

Endocrine disruptors: Phthalates and bisphenol A (BPA) disrupt hormonal signals and epigenetic mechanisms. Prenatal exposure to BPA lowers thyroid stimulating hormone and modifies the methylation of genes involved in brain development (Thakur and Chauhan, 2024). Transgenerational effects can also be caused by EDCs, which was also seen in animal models where phthalate exposure changed sperm methylations across several generations (Manikkam et al., 2013).

Oxidative stress and impaired methylation: A redox/methylation hypothesis suggests that oxidative stress caused by exposures to toxicants, breaks one-carbon metabolism and causes impairment of DNA methylation, which, in turn, alters the gene expression (Deth et al., 2008; Cheroni et al., 2020). ASD children have also been found with biomarkers of oxidative stress, mitochondrial dysfunction and reduced methylation capacity (Rossignol and Frye, 2012).

Collectively, the results highlight that in addition to causing direct harm to neural tissue, toxicants and EDCs interfere with epigenetic programming that supports normal neurodevelopment.

Gene x Environment Interactions:

Environmental exposures can alter the effect on the risk of ASD due to genetic susceptibility. An example is that air pollution and heavy metals are more harmful to individuals with polymorphisms in detoxification genes (Rusu et al., 2015). Similarly, neurodevelopment is highly sensitive to environmental factors due to a rare genetic mutation in chromatin regulating factors (Thakur and Chauhan, 2024).

Gene x environment (GxE) interactions tend to converge at epigenetic pathways. Research indicates that the effects of environmental insults, including maternal stress, toxicants, and nutrient deficiencies, disproportionately affect individuals who have certain genetic variants (Tordjman et al., 2014). Imaging also shows that risk alleles that relate to ASD are related to structural alterations of the brain, yet only behavioral symptoms appear in patients who are exposed to negative environments (Stamou et al., 2013).

This interaction is to imply that ASD is not due to isolated genetic and environmental factors but a dynamic interaction between them that is mediated by the process of epigenetics. This knowledge is important in precision medicine strategies because it determines subgroups that are most likely to be helped by specific therapies.

Transgenerational Epigenetic Inheritance

There is some emerging evidence that it is possible to transfer environmentally induced epigenetic modifications over generations even without further exposure (LaSalle et al., 2013; Kubota and Mochizuki, 2016). Animal experiments show that prenatal exposure to insecticides, social stress, or nutritional deficiencies lead to autism-like behaviors in both offspring and grand-offspring and result in methylation of neurodevelopmental genes at the DNA level (Manikkam et al., 2013).

Advanced paternal age is the example of transgenerational effect in humans, and the alterations of sperm methylation associated with the risk of ASD are maintained across generations (Masini et al., 2020). Models of alcohol and drug exposure also demonstrate the modification of ancestral exposures to methylation in the germline and the impact on the neurodevelopment of future generations (Finegersh and Rompala, 2015).

Even though the idea of multigenerational epigenetic inheritance is preliminary in humans, evidence supports that environmental exposures to ASD risk have long-term effects.

Biomarkers and Precision Medicine

Epigenetic marks can be useful biomarkers of risk in early ASD. Later ASD diagnosis has been linked to DNA methylation of the cord blood, placenta, and offspring saliva (Bakulski, 2019; Tremblay and Jiang, 2019). In ASD cohorts, there are OXTR and MECP2 loci with identical methylation changes (Loke et al., 2015).

Clinically, these biomarkers could help identify such risks earlier and also profile risks on a case-by-case basis. The combination of epigenetic markers and genetic and environmental data is the basis of precision medicine in ASD (LaSalle et al., 2013). Nevertheless, there are

still issues with standardizing assays, validating the markers between populations, and separating causal and consequential changes.

Interventions, Ethical Considerations, and Future Directions

Through the reversibility of epigenetic modifications, therapeutic opportunities are provided. Toxicant-induced changes in methylation could be reversed by nutritional supplementation (e.g., folate, vitamins C and E) (Rusu et al., 2015). Histone deacetylase inhibitors are a type of epigenetic drug currently being investigated in animals, but clinical translation has to be carefully considered due to developmental sensitivity (Kubota & Mochizuki, 2016). Other programs including enriched caregiving environments also demonstrate the potential to reverse negative epigenetic programming in the early stages of life (Strathearn et al., 2023).

Future studies ought to cover a few gaps:

1. longitudinal research studies that would monitor maternal exposures, epigenetic alterations, and ASD outcomes;
2. multi-omics studies involving the integration of genomics, epigenomics, transcriptomics, and metabolomics
3. studies of EDC mixtures, not single toxicants
4. ethical considerations of the application of epigenetics biomarkers in prevention and prediction.

Ethical issues are especially drastic. The epigenetic biomarkers are dangerous when relied on to predictively screen people without the necessary counseling and support. In addition, epigenome-based interventions should consider the benefits and possible unexpected effects since it is complicated to regulate genes throughout neurodevelopment (Torres et al., 2023).

DISCUSSION

A combination of genetic, epigenetic, environmental and clinical analysis data on autism spectrum disorder (ASD) demonstrates the disorder as a multifactorial neurodevelopmental disorder which cannot be attributed to one cause. Although genetic discoveries have brought forth tremendous gains, it has not been enough to address the broad variations of the disorder, sex variations, and the constantly growing prevalence rates. Rather, genetic predisposition interacts with the environmental factors by means of the epigenetic alterations that determine the expression of the genes. This view brings out the complexity of ASD and reveals why prevention, diagnosis, and treatment have proven to be difficult. The key themes have been addressed in this section and especially there are the implications of epigenetics, points of convergence and contradiction within the literature, clinical and translational potential, ethical issues, and future directions of research.

The Etiology of ASD: Genes to Epigenomes.

Early autism studies were mainly aimed at finding some special autism genes. Over 400 nonsyndromic genes and 100 syndromic-associated genes have been determined in large-scale genomic research (Grayson & Guidotti, 2015). These findings affirmed the role of genetics, although the impact of most individual variations is not large. Some of the variants are rare and not all people with such variants develop ASD. This generated a requirement of further explanations beyond the DNA sequence.

The model of epigenetics is more convincing since it explains how environmental exposures may influence neurodevelopment through regulation of gene expression. DNA methylation, histone modifications, and non-coding RNAs alter gene expression without altering DNA

sequence, and they are environmentally sensitive during development. Epigenetic modifications unlike fixed mutations are dynamic and reversible, thus, important during both risk and prevention. With the re-emphasis on the role of genes in ASD, it is now interpreted as the product of interplay between inherited genetically prone factors and environmental triggers.

Convergence in Evidence Streams

Epidemiological, molecular biology, and animal models all point in the same direction in support of the role of epigenetics in ASD. One of them is maternal folate supplementation. A number of epidemiological studies have concluded that ASD risk is reduced by periconceptual folic acid (Schmidt et al., 2011). This is facilitated by the mechanistic research carried out to demonstrate the role of folate in supplying Methyl groups that are needed in the process of DNA methylation (Deth et al., 2008). Collectively, these results justify the establishment of folate supplementation on the stabilization of the methylation of neurodevelopmental genes.

Air pollution is another example. Nitrogen oxides and particulate matter in the prenatal period are associated with increased risks of ASD (Volk et al., 2013). Molecular analysis demonstrates that pollutants may result in DNA methylation alteration in the oxidative stress and inflammatory pathways (Rusu et al., 2015). The exposure of animals to particulate matter has been confirmed to interfere with brain development and synaptic signaling. These three lines of evidence converge to the same mechanisms which increases confidence in the fact that epigenetics is a mediator.

Studies that are particularly helpful in determining causality are those of animals. As an example, mice prenatally exposed to valproic acid develop autism-like behavior and have abnormal histone acetylation (epigenetic process where an acetyl group is added to lysine residues on histone proteins, which weakens the electrostatic interaction between histones and DNA, leading to a looser, more open chromatin structure) of neural tissue (Choi et al., 2016). There is also human data evidence of higher risk of ASD in children who are exposed to valproic acid. This uniformity of study types shows that environmental exposures have the potential to directly cause epigenetic changes which result in the development of phenotypes similar to ASD.

Contradictions and Uncertainties

Not all findings are similar. Selective serotonin reuptake inhibitors (SSRI) are one such example. Epidemiological research indicates that in some cases maternal use of SSRI compounds leads to the risk of ASD, and in some cases the association is not noticed. SSRIs also modify the DNA methylation of serotonin pathways in animal research (Man et al., 2015), but this is hard to extrapolate to humans because of such confounding variables as depression in mothers.

Mixed evidence is also generated by endocrine disruptors like bisphenol A (BPA). BPA has a consistent detrimental impact on the animal models by altering the genes associated with brain development and hormone signaling DNA methylation (Thakur and Chauhan, 2024). Nevertheless, human population research is inconsistent due to variations in BPA exposure levels, inconsistency in exposure assessment techniques and lack of genetic susceptibility.

The other ambiguity is whether the epigenetic marks that are observed are causal or secondary. Numerous reports on postmortem brain tissue studies in ASD report a change in

methylation in genes associated with synaptic plasticity and neurotransmission (Loke et al., 2015). But it is still not clear whether these changes are a cause of ASD or they are just a result of living with an abnormal brain activity. It is necessary to conduct longitudinal studies that begin in pregnancy in order to establish cause and effect.

Sex-Specific Pathways and Vulnerabilities

ASD has other complexities in sex differences. Male patients are more commonly diagnosed, but women affected by ASD may exhibit worse adaptive functioning impairment as well as social communication. This implies that biological sex plays off with risk factors.

A potential cause is the fact that the hormones are different. DNA methylation and histone alterations are affected by estrogen and androgen signaling in brain development. Male Hormone pathways can be susceptible due to alterations in the epigenome, or protective against females. Placental activity also varies depending on sex and that could alter the effect of maternal exposures on fetal development.

Another factor has sex-specific implications of paternal age. There is more de novo mutations (genetic alteration that arises "from the beginning" in an individual, meaning it was not inherited from their parents but occurred spontaneously in a parent's egg or sperm, or in the fertilized egg itself) and epigenetic drift of sperms in older fathers. This is more pronounced among male offspring than female offspring (Masini et al., 2020). Knowing these sex-differentiated pathways will be significant in preventing and treating strategies.

Dynamic Gene-Environment Interactions

The concept of the joint action of genes and environment, rather than separate action is also a key point in ASD research. The Gene-environment (GxE) interactions can explain why different individuals with identical genetic variation do not develop ASD and why some children are more susceptible to environmental exposure than others.

For example, children with certain detoxification gene polymorphisms are more vulnerable to heavy metals and air pollution (Rusu et al., 2015). Similarly, uncommon mutations of chromatin regulators such as CHD8 seem to predispose people to become susceptible to environmental stresses (Thakur and Chauhan, 2024).

GxE effects are also supported using imaging studies. Children with ASD risk alleles sometimes show structural changes in the brain, but only those exposed to additional environmental triggers go on to develop behavioral symptoms (Stamou et al., 2013). This is a dynamic model of interaction which explains variability of ASD expression, and timing of exposure.

Clinical Translation: Biomarkers and Interventions

Epigenetic markers are potentially useful as clinical instruments. Multiple researchers have identified the presence of methylation differences in placenta, cord blood, or saliva that subsequently lead to ASD diagnosis (Bakulski, 2019; Tremblay and Jiang, 2019). Regulators of social behavior and synaptic development (OXTR and MECP2) are common loci that are usually affected. Such biomarkers may enable the earlier detection of children at risk, provided that these biomarkers are confirmed.

However, challenges remain. The reliability of existing biomarkers is limited by technical variation among laboratories, population variation, and the fact that it is hard to distinguish

between cause and effect. This will necessitate clinical implementation in larger cohorts, standardized techniques and cross-population validation.

Intervention measures are also emerging. Folate supplementation has protective effects and could prevent part of the epigenetic vulnerabilities. Antioxidant vitamins (C and E) can be used to decrease oxidative stresses and enhance the methylation capacity (Rusu et al., 2015). Pharmacological methods, including histone deacetylase inhibitors are under clinical tests in animal models but are hard to use safely in humans because of the widespread impact on gene expression (Kubota & Mochizuki, 2016). The non-pharmacological interventions, such as enriched caregiving environments and behavioral therapies, also demonstrate the potential to affect the epigenetic signature in a positive way (Strathearn et al., 2023).

Table 1: Summary of Key Findings on Environmental Epigenetic Interactions in Autism Spectrum Disorder (ASD)

Thematic Area	Core Findings and Insights	Representative Citations
1. Etiology & Heterogeneity	ASD (~1 in 36 U.S. children) arises from interacting genetic, epigenetic, and environmental factors.	APA (2013); Maenner et al. (2023)
2. Genetic & Epigenetic Basis	>500 ASD genes identified; epigenetic regulation explains phenotypic variability.	Bird (2007); LaSalle et al. (2013)
3. Maternal & Prenatal Factors	Nutrition, age, metabolic health, stress, and medications influence fetal methylation and ASD risk.	Schmidt et al. (2011); Masini et al. (2020)
4. Environmental Toxicants	Pollutants, metals, pesticides, BPA, and phthalates disrupt neurodevelopmental methylation; effects may be heritable.	Volk et al. (2013); Thakur & Chauhan (2024)
5. Gene × Environment Interactions	Genetic susceptibility modulates environmental impacts, supporting precision medicine.	Rusu et al. (2015); Stamou et al. (2013)
6. Transgenerational Effects	Epigenetic alterations from toxicants or stress can persist across generations.	Manikkam et al. (2013); Masini et al. (2020)
7. Biomarkers & Precision Medicine	Differential methylation (e.g., *OXTR*, *MECP2*) in perinatal tissues may serve as early biomarkers.	Loke et al. (2015); Bakulski (2019)
8. Interventions & Reversibility	Nutrients, antioxidants, HDAC inhibitors, and enriched environments may restore epigenetic balance.	Kubota & Mochizuki (2016); Strathearn et al. (2023)
9. Sex Differences	Males show higher prevalence; sex hormones and paternal age affect epigenetic sensitivity.	Guidotti & Grayson (2015); Masini et al. (2020)
10. Ethical & Societal Issues	Biomarker use and epigenetic therapies require ethical oversight; pollution control remains vital.	Torres et al. (2023); Rusu et al. (2015)
11. Future Directions	Multi-omics, longitudinal, and sex-stratified studies integrating ethics are needed.	Sections 16.1–16.6
12. Integrative Summary	ASD reflects gene–environment interplay via epigenetic mechanisms, enabling preventive and personalized strategies.	Overall synthesis

Transgenerational Perspectives

An increasing amount of evidence indicates that the impact of epigenetics could be intergenerational. Prenatal exposure of animals to pesticides, phthalates, or stress has been shown to lead to autism-like behavior in the offspring and grand-offspring, both with long-term changes in DNA methylation of germline cells (Manikkam et al., 2013).

Paternal age is indirect evidence for transgenerational effects in human beings. The patterns of sperm methylation in older fathers are linked to the higher risk of ASD in their children and some evidence indicates that the pattern can continue into each subsequent generation (Masini et al., 2020).

Transgenerational inheritance may occur such that the current environmental exposures have the potential to influence neurodevelopmental outcomes of several future generations. This underscores the pressing need to minimize the adverse exposures via public health and environment policies.

Moral and Societal aspects

Although the discoveries of epigenetics open new possibilities in early detection and prevention, the findings are also ethically problematic. Anticipating the application of biomarkers may cause stigmatization, discrimination or even psychological trauma within the family in case a child is referred to as a high risk. Such predictions can be detrimental in the absence of the right counseling and protection.

Intervention is another problem. Changing the DNA methylation or histone acetylation through epigenetic therapies might also produce unexpected effects, because both mechanisms control a large number of genes at once. As compared to a single-gene mutation, epigenetic regulation is context-dependent and broad, and this makes its manipulation in the clinical field risky. The development of such treatments should put safety and equity at the center of the ethical frameworks (Torres et al., 2023).

On the societal level, results highlight the significance of environmental regulations. Limiting exposure to toxicants, pesticides and endocrine disruptors is not just an ecological issue, but a health priority of neurodevelopmental health. Policy measures safeguarding pregnant women and young children against harmful exposures would alleviate ASD risk among the general population in a major avenue.

Future Research Directions

There are some directions which are essential to the development of this field:

- **Longitudinal Cohorts**: To compare exposures, epigenetic alterations and neurodevelopmental results across time, longitudinal studies of mothers and their children during pregnancy and early childhood are necessary.
- **Multi-Omics Integration**: Integrating genomic, epigenomic, transcriptomic, metabolomic, and microbiome data will be able to give a more global picture of ASD risk factors.
- **Mixture Studies**: These exposures in the real-world are combined with nutrition and stressors. Future research should focus on these mixtures, and not on individual exposures.
- **Cross-Species Comparisons**: Animal models give causality whereas human studies give relevance. Comparative research is required to fill the gap between the two.

- **Sex-Specific Analyses**: The studies should consider sex differences in susceptibility, biomarkers and outcomes.
- **Ethical Integration**: Ethical consideration must be present throughout biomarker development, risk prediction and intervention research.

Synthesis and Wider Implications

Taken together, there is evidence in the literature that ASD is a result of genetic vulnerability and exposure to environmental exposures that interact via epigenetic mechanisms. Imprints in DNA methylation, histone changes, and non-coding RNAs are all left by maternal nutrition, metabolic condition, stress, and toxicants and endocrine disruptors. These processes explain the variability in ASD expression and opportunities to prevent ASD.

Epigenetics changes the pattern of ASD to not purely genetic but a condition that has a reason to be changed. This creates opportunities regarding early screening, prevention at the individual level and interventions. Effective translation will however be based on proper validation, ethics, and policies that minimise harmful exposures in the environment.

CONCLUSION

Autism Spectrum Disorder (ASD) is a complex condition that develops through the combined effects of genes and the environment, and it is to a large degree mediated by epigenetics. Neurodevelopment is influenced by the intersection of maternal nutrition, metabolic condition, age, psychosocial stress, and toxicant and endocrine disruptor exposure on DNA methylation, histone modification and non-coding RNA pathways. These effects are regulated by genetic predisposition, and the transgenerational inheritance highlights that effects of environmental affronts are long-lasting.

The interpretation of ASD in the light of epigenetics can be used to explain why symptoms and severity vary in different individuals and why genetic risks only result in ASD in specific environmental conditions. It further emphasizes that some molecular alterations can be reversible, which brings a possibility of prevention and early interventions. Epigenetic biomarkers have a potential in early detection and personalized medicine although the clinical utility of epigenetic biomarkers needs further validation.

Finally, deciphering the role of environmental factors in ASD risk by epigenetic forces, could provide new opportunities in effective prevention, earlier diagnosis, and intervention- and could bring us closer to precision medicine in the treatment of autism.

REFERENCES

American Psychiatric Association. (2013). *Diagnostic and statistical manual of mental disorders* (5th ed.). American Psychiatric Publishing.

Bakulski, K. M. (2019). DNA methylation as an epigenetic biomarker of autism spectrum disorder. *Epigenomics*, 11(11), 1221–1234.

Beversdorf, D. Q., Stevens, H. E., & Jones, K. L. (2018). Prenatal stress, maternal immune dysregulation, and their association with autism spectrum disorders. *Neuroscience & Biobehavioral Reviews*, 95, 428–445.

Bird, A. (2007). Perceptions of epigenetics. *Nature*, 447(7143), 396–398.

Centers for Disease Control and Prevention (CDC). (2012). *Prevalence of autism spectrum disorders—Autism and Developmental Disabilities Monitoring Network, 14 sites, United States, 2008*. *MMWR Surveillance Summaries*, 61(3), 1–19.

Cheroni, C., Caporale, N., & Testa, G. (2020). Autism spectrum disorder at the crossroad between genes and environment: Contributions, convergences, and interactions in ASD developmental pathophysiology. *Molecular Autism*, 11, 69.

Choi, C. S., Gonzales, E. L., Kim, K. C., Yang, S. M., Kim, J. W., Mabunga, D. F., & Shin, C. Y. (2016). The critical period of valproate exposure to induce autistic symptoms in Sprague-Dawley rats. *Toxicology Letters*, 245, 67–78.

Deth, R., Muratore, C., Benzecry, J., Power-Charnitsky, V. A., & Waly, M. (2008). How environmental and genetic factors combine to cause autism: A redox/methylation hypothesis. *Neurotoxicology*, 29(1), 190–201.

Fatemi, S. H., Snow, A. V., Stary, J. M., Araghi-Niknam, M., Reutiman, *T.* J., Lee, S., & Pearce, D. A. (2005). Reelin signaling is impaired in autism. *Biological Psychiatry*, 57(7), 777–787.

Finegersh, A., & Rompala, G. R. (2015). Transmission of stress-induced pathologies through epigenetic inheritance: Focus on alcohol. *Biological Psychiatry*, 78(4), 309–316.

Gregory, S. G., Connelly, J. J., Towers, A. J., Johnson, J., Biscocho, D., Markunas, C. A., & Pericak-Vance, M. A. (2009). Genomic and epigenetic evidence for oxytocin receptor deficiency in autism. *BMC Medicine*, 7, 62.

Grayson, D. R., & Guidotti, A. (2015). The dynamics of DNA methylation in schizophrenia and related psychiatric disorders. *Neuropsychopharmacology*, 40(1), 211–223.

Guidotti, A., & Grayson, D. R. (2015). Epigenetic mechanisms in schizophrenia and major mental illness. *Neuropsychopharmacology*, 40(1), 236–237.

Guo, B. Q., Zhao, Y., Wu, C. H., & Zhang, Q. (2018). Zinc and magnesium deficiency affect neurodevelopment: Evidence from human and animal studies. *Frontiers in Neuroscience*, 12, 912.

Keil, K. P., & Lein, P. J. (2016). DNA methylation: A mechanism linking environmental chemical exposures to risk of autism spectrum disorders? *Environmental Epigenetics*, 2(1), dvv012.

Kinney, D. K., Barch, D. H., Chayka, B., Napoleon, S., & Munir, K. M. (2010). Environmental risk factors for autism: Do they help cause de novo genetic mutations that contribute to the disorder? *Medical Hypotheses*, 74(1), 102–106.

Kubota, *T.*, & Mochizuki, K. (2016). Epigenetic effect of environmental factors on autism spectrum disorders. *Environmental Health and Preventive Medicine*, 21(6), 554–562.

Kundakovic, M., & Champagne, F. A. (2015). Epigenetic perspective on the developmental effects of bisphenol A. *Brain, Behavior, and Immunity*, 43, 92–97.

LaSalle, J. M., Powell, W. *T.*, & Yasui, D. H. (2013). Epigenetic layers and players underlying neurodevelopment. *Trends in Neurosciences*, 36(8), 460–470.

Loke, Y. J., Hannan, A. J., & Craig, J. M. (2015). The role of epigenetic change in autism spectrum disorders. *Frontiers in Neurology*, 6, 107.

Man, K. K. C., Tong, H. H. Y., Wong, L. Y. L., Chan, E. W., Simonoff, E., Wong, I. C. K., & Bouvy, J. (2015). Exposure to selective serotonin reuptake inhibitors during pregnancy and risk of autism spectrum disorder in children: A systematic review and meta-analysis of observational studies. *Neuroscience & Biobehavioral Reviews*, 49, 82–89.

Maenner, M. J., Shaw, K. A., Bakian, A. V., et al. (2023). Prevalence and characteristics of autism spectrum disorder among children aged 8 years—Autism and Developmental Disabilities Monitoring Network, 11 Sites, United States, 2020. *MMWR Surveillance Summaries*, 72(2), 1–14.

Manikkam, M., Tracey, R., Guerrero-Bosagna, C., & Skinner, M. K. (2013). Plastics derived endocrine disruptors (BPA, DEHP, and DBP) induce epigenetic transgenerational

inheritance of obesity, reproductive disease, and sperm epimutations. *PLoS ONE*, 8(1), e55387.

Masini, E., Loi, E., Vega-Benedetti, A. F., Carta, M., Doneddu, G., Fadda, R., & Meloni, A. (2020). An overview of autism spectrum disorder etiology and epigenetic mechanisms. *International Journal of Molecular Sciences*, 21(21), 8290.

Rusu, V., Bibire, N., Popa, C., & Mogoanta, L. (2015). Environmental influences and DNA methylation in autism spectrum disorders. *Romanian Journal of Morphology and Embryology*, 56(3), 989–995.

Roman, G. C., Ghassabian, A., Bongers-Schokking, J. J., Jaddoe, V. W., Hofman, A., de Rijke, Y. B., & Tiemeier, H. (2013). Association of gestational maternal hypothyroxinemia and increased autism risk. *Annals of Neurology*, 74(5), 733–742.

Rossignol, D. A., & Frye, R. E. (2012). Mitochondrial dysfunction in autism spectrum disorders: A systematic review and meta-analysis. *Molecular Psychiatry*, 17(3), 290–314.

Sandin, S., Lichtenstein, P., Kuja-Halkola, R., Larsson, H., Hultman, C. M., & Reichenberg, A. (2017). The heritability of autism spectrum disorder. *JAMA*, 318(12), 1182–1184.

Schaevitz, L. R., & Berger-Sweeney, J. (2012). Gene–environment interactions and epigenetic pathways in autism: The importance of early life social experiences. *Neuroscience & Biobehavioral Reviews*, 36(4), 1033–1042.

Schmidt, R. J., Hansen, R. L., Hartiala, J., Allayee, H., Schmidt, L. C., Tancredi, D. J., & Hertz-Picciotto, I. (2011). Prenatal vitamins, one-carbon metabolism gene variants, and risk for autism. *Epidemiology*, 22(4), 476–485.

Shelton, J. F., Geraghty, E. M., Tancredi, D. J., Delwiche, L. D., Schmidt, R. J., Ritz, B., & Hertz-Picciotto, I. (2014). Neurodevelopmental disorders and prenatal residential proximity to agricultural pesticides: The CHARGE study. *Environmental Health Perspectives*, 122(10), 1103–1109.

Stamou, M., Streifel, K. M., Goines, P. E., & Lein, P. J. (2013). Neuronal connectivity as a convergent target of gene × environment interactions that confer risk for autism spectrum disorders. *Neurotoxicology and Teratology*, 36, 3–16.

Strathearn, L., Fonagy, P., Amico, J., & Montague, P. R. (2023). Enriched caregiving and neurobiological plasticity: Implications for early interventions in autism. *Nature Reviews Neuroscience*, 24(2), 79–93.

Thakur, V., & Chauhan, A. (2024). Environmental toxicants and epigenetic dysregulation in autism spectrum disorders. *Frontiers in Cellular Neuroscience*, 18, 132145.

Tordjman, S., Somogyi, E., Coulon, N., Kermarrec, S., Cohen, D., Bronsard, G., & Lenoir, P. (2014). Gene × environment interactions in autism spectrum disorders: Role of epigenetic mechanisms. *Frontiers in Psychiatry*, 5, 53.

Tremblay, M. W., & Jiang, Y. H. (2019). DNA methylation and susceptibility to autism spectrum disorder. *Annual Review of Medicine*, 70, 151–166.

Torres, E. B., Denisova, K., & Zhao, W. (2023). Ethical frontiers of epigenetic interventions in neurodevelopmental disorders. *Neuroethics*, 16(3), 247–264.

Vellingiri, B., Suriyanarayanan, S., Subramaniam, M. D., Jayaramayya, K., Iyer, M., Narayanasamy, A., & Govindaraj, R. (2022). Role of maternal micronutrients and prenatal vitamins in autism: A review. *Frontiers in Neuroscience*, 16, 863259.

Volk, H. E., Lurmann, F., Penfold, B., Hertz-Picciotto, I., & McConnell, R. (2013). Traffic-related air pollution, particulate matter, and autism. *JAMA Psychiatry*, 70(1), 71–77.

Xu, G., Jing, J., Bowers, K., Liu, B., & Bao, W. (2014). Maternal diabetes and the risk of autism spectrum disorders in the offspring: A systematic review and meta-analysis. *Journal of Autism and Developmental Disorders*, 44(4), 766–775.

Ziats, M. N., & Rennert, O. M. (2014). Identification of differentially expressed microRNAs across the developing human brain. *Molecular Psychiatry*, 19(7), 848–852.

Acknowledgment
The author(s) appreciates all those who participated in the study and helped to facilitate the research process.

Conflict of Interest
The author(s) declared no conflict of interest.

How to cite this article: Sivanandam, S. (2025). Epigenetic Pathways Linking Environmental Exposures to Autism Spectrum Disorder Risk. *International Journal of Indian Psychology*, *13*(4), 1629-1643. DIP:18.01.150.20251304, DOI:10.25215/1304.150